Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma

Affiliations

• ¹ Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
• ² Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
• ³ Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
• ⁴ Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
• ⁵ Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA.
• ⁶ Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, USA.
• ⁷ Center for Secure Artificial Intelligence For hEalthcare (SAFE), Center for Precision Health, School of Biomedical Informatics, University of Texas Health Science Center Houston, Houston, TX, USA.
• ⁸ Department of Neurological Surgery, Northwestern University, Chicago, IL, USA.
• ⁹ Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA. klisch@bcm.edu.
• ¹⁰ Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. klisch@bcm.edu.
• ¹¹ Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA. akash.patel@bcm.edu.
• ¹² Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, USA. akash.patel@bcm.edu.
• ¹³ Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA. akash.patel@bcm.edu.